Eric Gibert
Eric Gibert has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Rousseau
Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), Saint Antoine Hospital, Assistance Publique-Hopitaux de Paris, Paris, France
1 shared publication - Alice Courties
Department of Rheumatology, AP-HP Saint-Antoine Hospital, Sorbonne University, Saint-Antoine Research Centre, Paris, France
1 shared publication - Béatrice Banneville
Service de Rhumatologie, Hôpital Pitié Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne Université, 75013 Paris, France
1 shared publication - Camille Chesnel
Sorbonne Université, GRC‐01 GREEN Service de Neuro‐urologie, Hôpital Pitié Salpêtrière Paris France
1 shared publication - Camille Deprouw
Service de Rhumatologie, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris (AP-HP), 75012 Paris, France
1 shared publication - Emmanuel Maheu
Sorbonne Université, APHP, Department of Rheumatology, Hôpital Saint-Antoine, Paris, France
1 shared publication
Latest Publications
- Open Access
- 18 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (4) , 1087
Effect of Transcutaneous Vagus Nerve Stimulation in Erosive Hand Osteoarthritis: Results from a Pilot Trial
Beyond its effect on vegetative functions, the activation of the vagus nerve inhibits inflammation and reduces pain signaling. The aim of this open-label pilot study was to determine the efficacy and tolerance of transcutaneous auricular VNS (taVNS) on erosive hand osteoarthritis (EHOA) symptoms. Symptomatic EHOA patients with hand pain VAS ≥ 40/100 mm and ≥1 interphalangeal swollen joint(s) were included. The taVNS was performed for 4 weeks using an auricular electrode applied one hour per day and connected to a TENS device with pre-established settings. Clinical efficacy was evaluated by changes between baseline and at 4 weeks with hand pain VAS and the functional index FIHOA score, using a Wilcoxon t-test. The treatment tolerance was also evaluated. Eighteen patients (median age 69 years old, 83% women) were analyzed. At baseline, hand pain VAS was 60 mm [IQR 50; 78.2] and FIHOA 15 [10.7; 20.2]. After 4 weeks, taVNS significantly reduced hand pain VAS, with a median decrease of 23.5 mm [7.7; 37.2] (p = 0.001), as well as FIHOA, with a median decrease of 2 points [0.75; 5.2] (p = 0.01). No serious adverse events were reported. One patient stopped taVNS because of auricular discomfort. This first proof-of-concept trial indicated that taVNS is feasible and may decrease joint inflammation and clinical symptoms in EHOA, arguing for a randomized controlled study versus sham stimulation.
- 18 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (4) , 1087
Open AccessEffect of Transcutaneous Vagus Nerve Stimulation in Erosive Hand Osteoarthritis: Results from a Pilot Trial
Beyond its effect on vegetative functions, the activation of the vagus nerve inhibits inflammation and reduces pain signaling. The aim of this open-label pilot study was to determine the efficacy and tolerance of transcutaneous auricular VNS (taVNS) on erosive hand osteoarthritis (EHOA) symptoms. Symptomatic EHOA patients with hand pain VAS ≥ 40/100 mm and ≥1 interphalangeal swollen joint(s) were included. The taVNS was performed for 4 weeks using an auricular electrode applied one hour per day and connected to a TENS device with pre-established settings. Clinical efficacy was evaluated by changes between baseline and at 4 weeks with hand pain VAS and the functional index FIHOA score, using a Wilcoxon t-test. The treatment tolerance was also evaluated. Eighteen patients (median age 69 years old, 83% women) were analyzed. At baseline, hand pain VAS was 60 mm [IQR 50; 78.2] and FIHOA 15 [10.7; 20.2]. After 4 weeks, taVNS significantly reduced hand pain VAS, with a median decrease of 23.5 mm [7.7; 37.2] (p = 0.001), as well as FIHOA, with a median decrease of 2 points [0.75; 5.2] (p = 0.01). No serious adverse events were reported. One patient stopped taVNS because of auricular discomfort. This first proof-of-concept trial indicated that taVNS is feasible and may decrease joint inflammation and clinical symptoms in EHOA, arguing for a randomized controlled study versus sham stimulation.
- 1 March 2007
- Published by Springer Nature in La Lettre de Médecine Physique et de Réadaptation
- Vol. 23 (1) , 22-29
Myélographie et saccoradiculographie
- 1 March 2007
- Published by Springer Nature in La Lettre de Médecine Physique et de Réadaptation
- Vol. 23 (1) , 22-29
Myélographie et saccoradiculographie